Multiple Myeloma Clinical Trials

A listing of 178 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 178 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Depressive disorder Clinical Study

Recruiting

A clinical study for people that suffer with Depressive disorder

Conditions:

Depressive disorder

Learn More

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma

NCT04835129

Recruiting

This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: The University of Alabama at Birmingham, Birmingham, Alabama +1 locations

Conditions: Multiple Myeloma

Learn More ›

Hypofractionation (Radiation) Trial for Multiple Myeloma

NCT06270888

Recruiting

This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma. Because participants in this study will receive a shortened radiation course, each daily treatment dose that is delivered would be slig... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: The University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Conditions: Multiple Myeloma

Learn More ›

Biomarkers of AKI in Patients Receiving Daratumumab

NCT06549634

Recruiting

The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy. To establish whether these biomarkers serve to aid in early detection and prevention of AKI... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: Brigham and Women's Hospital, Boston, Massachusetts

Conditions: Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy

Learn More ›

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

NCT06066346

Recruiting

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Multiple Myeloma

Learn More ›

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

NCT02291848

Recruiting

This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune cells known as T lymphocytes.This research study uses special immune system cells called tumor asso... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Harris Health Ben Taub Hospital, Houston, Texas +2 locations

Conditions: Multiple Myeloma

Learn More ›

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Recruiting

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/28/2025

Locations: Local Institution, Birmingham, Alabama +197 locations

Local Institution, Birmingham, Alabama

Local Institution - 0021, Birmingham, Alabama

Local Institution - 0013, Muscle Shoals, Alabama

Local Institute, Goodyear, Arizona

Local Institution - 0023, Anaheim, California

Local Institution, Anaheim, California

Local Institution - 0045, Burbank, California

Local Institution, Corona, California

Local Institution - 0048, Downey, California

Local Institution - 0052, Fountain Valley, California

Local Institute, Los Angeles, California

Local Institute, Santa Rosa, California

Local Institution - 0051, Santa Rosa, California

Local Institution - 0057, Washington, District of Columbia

Florida Cancer Specialists & Research Institute, Brooksville, Florida

Local Institution, Brooksville, Florida

Local Institution - 0044, Fort Lauderdale, Florida

Local Institution - 0017, Jacksonville, Florida

Local Institution, Jacksonville, Florida

Local Institution - 0046, Savannah, Georgia

Local Institute, Valdosta, Georgia

Local Institution - 0047, Valdosta, Georgia

Local Institution, Skokie, Illinois

Local Institution - 0041, Springfield, Illinois

Local Institution - 0012, Urbana, Illinois

Local Institution - 0058, Anderson, Indiana

Local Institution - 0011, Indianapolis, Indiana

Local Institution, Indianapolis, Indiana

Local Institution - 0061, Des Moines, Iowa

Local Institute, Sioux City, Iowa

Local Institution - 0018, Sioux City, Iowa

Local Institution - 0062, Lexington, Kentucky

Local Institution - 0064, London, Kentucky

Local Institute, Louisville, Kentucky

Local Institution - 0042, Louisville, Kentucky

Cancer Center of Acadiana at Lafayette General Health, Lafayette, Louisiana

Local Institution, Lafayette, Louisiana

Local Institution - 0009, Shreveport, Louisiana

Local Institution, Shreveport, Louisiana

Local Institution, Minneapolis, Minnesota

Local Institution - 0030, Woodbury, Minnesota

Local Institution - 0059, Jackson, Mississippi

Local Institute, Southaven, Mississippi

Local Institute, Kansas City, Missouri

Local Institution - 0050, Kansas City, Missouri

Local Institution - 0037, Missoula, Missouri

Local Institute, Saint Joseph, Missouri

Local Institution - 0015, Saint Louis, Missouri

Local Institution, Saint Louis, Missouri

Local Institution - 0020, Springfield, Missouri

Local Institution, Springfield, Missouri

Local Institute, Missoula, Montana

Local Institution - 0060, Lincoln, Nebraska

Local Institute, Omaha, Nebraska

Local Institution - 0024, Omaha, Nebraska

Local Institution - 008, Does Not Exist, New Jersey

Generic Country - Canada, No City Provided, New Jersey

Generic Country - France, No City Provided, New Jersey

Generic Country - Germany, No City Provided, New Jersey

Generic Country - Italy, No City Provided, New Jersey

Generic Country - UK, No City Provided, New Jersey

Generic Country - USA, No City Provided, New Jersey

Local Institution - 0049, Stony Brook, New York

Local Institute, Cary, North Carolina

Local Institution - 0033, Cary, North Carolina

Local Institution - 0010, Gastonia, North Carolina

Local Institution, Gastonia, North Carolina

Local Institute, Canton, Ohio

Local Institution - 0022, Canton, Ohio

Local Institute, Cleveland, Ohio

Local Institution - 0019, Cleveland, Ohio

Local Institute, Tulsa, Oklahoma

Tulsa Cancer Institute PLLC, Tulsa, Oklahoma

Local Institute, Portland, Oregon

Local Institute, Pottstown, Pennsylvania

Local Institution - 0043, Pottstown, Pennsylvania

Local Institute, Charleston, South Carolina

Local Institution - 0016, Charleston, South Carolina

Local Institute, Knoxville, Tennessee

Local Institution - 0038, Knoxville, Tennessee

Local Institution - 0035, Memphis, Tennessee

Local Institution, Memphis, Tennessee

Local Institute, Amarillo, Texas

Local Institution - 0029, Amarillo, Texas

Local Institution - 0063, Bryan, Texas

Local Institute, Corpus Christi, Texas

Local Institute, Dallas, Texas

Local Institution - 0025, Dallas, Texas

Local Institute, Dallas, Texas

Local Institution - 0014, Dallas, Texas

Local Institution - 0032, Garland, Texas

Local Institute, San Antonio, Texas

Local Institution - 0027, San Antonio, Texas

Local Institute, Sherman, Texas

Local Institution - 0028, Sherman, Texas

Local Institute, Seattle, Washington

Local Institution - 0039, Seattle, Washington

Local Institute, Spokane, Washington

Local Institution - 0026, Spokane, Washington

Local Institute, Yakima, Washington

Local Institution - 0031, Yakima, Washington

Local Institution - 0065, Toronto, Ontario

Local Institute, Toronto, Ontario

Local Institution - 0066, Toronto, Ontario

Local Institute, Weston, Ontario

Local Institute, Blois, Not set

Local Institution - 0106, Cannes Cedex, Not set

Local Institution - 0099, Chalon sur Saone, Not set

Local Institute, Chalon sur Saone, Not set

Local Institute, La Roche sur Yon, Not set

Local Institution - 0100, La Roche-sur-yon Cedex 9, Not set

Local Institution - 0104, Limoges, Not set

Local Institute, Limoges, Not set

Local Institution - 0105, Meaux, Not set

Local Institute, Meaux, Not set

Local Institution - 0102, Nantes, Not set

Local Institute, Nantes, Not set

Local Institution - 0101, Perigueux, Not set

Local Institute, Rennes, Not set

Local Institution - 0103, Rennes, Not set

Local Institute, Heidelberg, Baden-Württemberg

Local Institute, Hamm, Nordrhein-Westfalen

Local Institute, Aschaffenburg, Not set

Local Institution - 0072, Aschaffenburg, Not set

Local Institute, Berlin, Not set

Local Institution - 0068, Berlin, Not set

Local Institution - 0081, Bielefeld, Not set

Local Institution, Bochum, Not set

Local Institute, Dresden, Not set

Local Institution - 0069, Dresden, Not set

Local Institution - 0082, Dresden, Not set

Local Institution - 0077, Frankfurt-oder, Not set

Local Institution - 0084, Gelsenkirchen, Not set

Local Institution - 0089, Goslar, Not set

Local Institution - 0070, Hamm, Not set

Local Institution - 0071, Heidelberg, Not set

Local Institution - 0088, Kiel, Not set

Local Institution - 0087, Köln, Not set

Local Institution - 0076, Ludwigsburg, Not set

Local Institute, Magdeburg, Not set

Local Institution - 0067, Magdeburg, Not set

Local Institution - 0073, Muenchen, Not set

Local Institution - 0079, Mutlangen, Not set

Local Institute, München, Not set

Local Institution - 0080, Oldenburg, Not set

Local Institution - 0075, Reutlingen, Not set

Local Institution - 0074, Rostock, Not set

Local Institution - 0086, Rostock, Not set

Local Institute, Rostock, Not set

Local Institution - 0078, Traunstein, Not set

Local Institution - 0085, Wiesbaden, Not set

Local Institute, Pesaro, Pesaro E Urbino

Local Institute, Ancona, Not set

Local Institution - 0108, Ancona, Not set

Local Institute, Ancona, Not set

Local Institution - 0119, Cagliari, Not set

Local Institute, Cagliari, Not set

Local Institution - 0111, Firenze, Not set

Local Institute, Firenze, Not set

Local Institute, Lecce, Not set

Local Institution - 0113, Lecce, Not set

Local Institution - 0124, Messina, Not set

Local Institution - 0120, Messina, Not set

Local Institute, Milano, Not set

Local Institution - 0116, Milano, Not set

Local Institute, Napoli, Not set

Local Institution - 0114, Napoli, Not set

Local Institution - 0115, Pesaro, Not set

Local Institution - 0121, Pescara, Not set

Local Institute, Roma, Not set

Local Institution - 0109, Roma, Not set

Local Institution - 0110, Roma, Not set

Local Institution - 0118, Roma, Not set

Local Institution, Roma, Not set

Local Institution - 0122, San Giovanni Rotondo (FG), Not set

Local Institution - 0107, Terni, Not set

Local Institute, Terni, Not set

Local Institute, Torino, Not set

Local Institution - 0112, Torino, Not set

Local Institute, Vicenza, Not set

Local Institution - 0117, Vicenza, Not set

Local Institute, Truro, Cornwall

Local Institution - 0098, Harrow, Greater London

Local Institute, Leeds, Not set

Local Institution - 0092, Leeds, Not set

Local Institution - 0091, Liverpool, Not set

Local Institution, Liverpool, Not set

Local Institution - 0097, Manchester, Not set

Local Institute, Nottingham, Not set

Local Institution - 0095, Nottingham, Not set

Local Institute, Stafford, Not set

Local Institution - 0096, Stafford, Not set

Local Institute, Swansea, Not set

Local Institution - 0093, Swansea, Not set

Local Institution - 0094, Truro, Not set

Conditions: Multiple Myeloma

Learn More ›

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555

Recruiting

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama

Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia

Learn More ›

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT05706766

Recruiting

The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, physical capacity, patient reported outcomes, and cardiometabolic health outcomes. The names of the study interventions involved in this study are: * Prehabilitative aerobic and resistance exercise (PA... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations

Conditions: Multiple Myeloma, Stem Cell Transplant Complications

Learn More ›

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

NCT06296368

Recruiting

The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.

Gender:

ALL

Ages:

60 years and above

Trial Updated:

01/23/2025

Locations: Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers

Learn More ›

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency

NCT04240054

Recruiting

This is a single-arm, open-label phase II study with a safety lead-in phase.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/22/2025

Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Multiple Myeloma

Learn More ›

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

NCT00582621

Recruiting

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease a... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/21/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +5 locations

Conditions: Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer

Learn More ›

Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

NCT05344833

Recruiting

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: University of Illinois at Chicago, Chicago, Illinois

Conditions: Multiple Myeloma

Learn More ›